The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug

Being the second most common type of primary bone malignancy in children and adolescents, Ewing Sarcoma (ES) encounters the dilemma of low survival rate with a lack of effective treatments. As an emerging approach to combat cancer, RNA therapeutics may expand the range of druggable targets. Since th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dai-Feng, Yuan, Ying, Tu, Mei-Juan, Hu, Xiang, Li, Yi-Zhou, Yi, Wan-Rong, Li, Peng-Cheng, Zhao, Yong, Cheng, Zhen, Yu, Ai-Ming, Jian, Chao, Yu, Ai-Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052494/
https://www.ncbi.nlm.nih.gov/pubmed/32161722
http://dx.doi.org/10.3389/fonc.2020.00222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052494/
https://www.ncbi.nlm.nih.gov/pubmed/32161722
http://dx.doi.org/10.3389/fonc.2020.00222

Ejemplares similares